Long-Term Follow-up Study for Patients Previously Treated With JCAR015

Juno Therapeutics

Status: Completed

Conditions: Acute Lymphoblastic Leukemia

Treatments: Genetic: JCAR015

Study type: Observational

Funder types: Industry

Identifiers

NCT02813252

015002

Details and patient eligibility

About

This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival.

Enrollment: 15 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have received at least one dose of JCAR015 in a previous treatment protocol.
• Patients who have provided informed consent for the long-term follow-up study prior to study participation.

Exclusion criteria

• None. All patients who have previously received JCAR015 treatment are eligible for this long-term follow-up study.

Trial design

15 participants in 1 patient group

JCAR015-treated

Description:

Patients who received previous treatment with JCAR015

Treatment:

Genetic: JCAR015